China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced a licensing agreement with Japanese firm Kaneka Corporation, securing exclusive patent rights and technical know-how for two skin patch drugs, SN001 and SN002. The agreement covers the Chinese mainland, Hong Kong, and Macao markets, expanding the reach of these innovative drugs in the region.
Financial Terms and Royalty Structure
As per the agreement, Sun-Novo will pay Kaneka a license fee in installments. Following the approval of the drugs for marketing, the Chinese company will pay a certain percentage of royalties to Kaneka based on annual sales. This structure aligns with industry standards for licensing agreements, ensuring a fair exchange of intellectual property and financial compensation.
SN001 and SN002: Transdermal Patches for Neurological and Psychiatric Disorders
SN001 and SN002 are transdermal patches designed for the treatment of neurological and psychiatric disorders, respectively. These patches offer a significant advantage over oral formulations as they are absorbed through the skin, providing excellent medication convenience for patients who have difficulty swallowing. Additionally, transdermal patches are expected to reduce the incidence of gastrointestinal adverse reactions such as nausea and vomiting, improving patient compliance and overall treatment experience.-Fineline Info & Tech
